News
1 October 2026
Fonko Strengthens Indonesia’s Oncology Industry Capacity
JAKARTA — PT Fonko International Pharmaceuticals has recorded several key milestones in the development of oncology drug manufacturing in Indonesia. These achievements include securing European Union Good Manufacturing Practice (EU GMP) certification in 2025, developing a range of "first copy" products for cancer therapy, and obtaining halal certification for its…
25 September 2026
Consistently Maintaining Halal Standards, Dexa Group Wins IHYA 2026
TANGERANG — PT Ferron Par Pharmaceuticals, a member of Dexa Group, has won the 2026 Indonesia Halal Industry Award (IHYA) from the Ministry of Industry of the Republic of Indonesia in the Large Industrial Enterprise Category, Subcategory of Best Pharmaceuticals and Traditional Medicines. This award recognizes Dexa Group’s consistency in…
24 September 2026
From Medications to Facilities, Ferron Strengthens Support for Cancer Patients
JAKARTA — Indonesia recorded 474,083 new cases and 283,299 deaths due to cancer, according to 2024 Global Cancer Observatory (GLOBOCAN) data. This situation underscores the critical role of Ferron Par Pharmaceuticals in expanding its support for cancer patients—from delivering access to medications to strengthening chemotherapy support facilities through the provision…
28 October 2023
Stunting Rate Reaches 34,9%, Dexa Medica Collaborates with BKKBN in Educating Hundreds of Midwives in Jember
In the 2024 State Budget and Revenue (APBN), President Joko Widodo allocated IDR 186.4 trillion or 5.6 percent for the health sector. One of the primary goals is to reduce the prevalence of stunting in Indonesia to 14 percent by 2024. To accelerate the stunting reduction target of 14 percent…
28 October 2023
Prof. Raymond Tjandrawinata, a Pioneer of Indonesian Indigenous Modern Medicine Provides Education in Stunting Prevention
The 2022 Indonesian Nutrition Status Survey (SSGI) reported that the prevalence of stunting in Jember reached 34.9%, the highest in East Java. Pharmacologist Prof. Raymond R. Tjandrawinata provided education at the Education on Stunting Intervention for Midwives program in Jember Regency to accelerate the stunting reduction to 14% by 2024…
23 October 2023
Dexa Group Continues Participating in the Global Market by Attending the 38th Trade Expo Indonesia
Dexa Group participated at the 38th Trade Expo Indonesia as a sign of commitment and continuity in the export industry. Dexa Group took part by setting up a booth with top export products such as Indonesia Indigenous Modern Medicine (OMAI), Boska, and Glucient SR. Mrs. Gracianti Soetikno, Commissioner of Dexa Group,…
10 September 2023
Dexa Medica and the Indonesian National Army (TNI AD) Collaborate to Reduce Stunting
Dexa Medica continues collaborating with diverse stakeholders to play an active role in the program to reduce stunting to 14% by 2024. Dexa Medica collaborated with the Indonesian National Army (TNI AD) and the Family Coordinating Agency National Planning (BKKBN) on this occasion to launch the e-Stuntad and e-Posyandu apps…
5 September 2023
Dexa Medica Halal Product Guarantee System Wins Halal Award
Dexa Group once again received the Halal Award from the Lembaga Pengkajian Pangan Obat-obatan dan Kosmetika Majelis Ulama Indonesia (LPPOM MUI) in the Best Social Contribution on Halal environment category, demonstrating its dedication to establishing a halal environment in Indonesia. "I congratulate all companies and business actors nominated for and…
28 August 2023
Dexa Medica Contributes to PIT IAI, Support Advancement, and Faces Pharmaceutical Challenges
Dexa Medica participated in the Annual Scientific Meeting (PIT) of the Ikatan Apoteker Indonesia (IAI) in Solo City, Central Java, on August 24 -26, 2023, as a form of collaboration in supporting advancement and facing challenges in the pharmaceutical and health fields in accordance with the Dexa Medica's core purpose,…
23 August 2023
BKKBN and Dexa Medica Educate Blitar Midwife on The Importance of Breast Milk in Overcoming Stunting
In the 2024 Rancangan Anggaran Belanja dan Pendapatan Negara (RAPBN), President Joko Widodo allotted IDR 186.4 trillion, or 5.6 percent, towards the healthcare system. One of the primary goals is to reduce the prevalence of stunting in Indonesia by 14 percent by 2024. In this context, Hasto Wardoyo, the Head…